Syntheses and Evaluation of Carbon-11- and Fluorine-18-Radiolabeled pan-Tropomyosin Receptor Kinase (Trk) Inhibitors: Exploration of the 4‑Aza-2-oxindole Scaffold as Trk PET Imaging Agents
journal contributionposted on 18.02.2015, 00:00 by Vadim Bernard-Gauthier, Arturo Aliaga, Antonio Aliaga, Mehdi Boudjemeline, Robert Hopewell, Alexey Kostikov, Pedro Rosa-Neto, Alexander Thiel, Ralf Schirrmacher
Tropomyosin receptor kinases (TrkA/B/C) are critically involved in the development of the nervous system, in neurological disorders as well as in multiple neoplasms of both neural and non-neural origins. The development of Trk radiopharmaceuticals would offer unique opportunities toward a more complete understanding of this emerging therapeutic target. To that end, we first developed [11C]GW441756 ([11C]9), a high affinity photoisomerizable pan-Trk inhibitor, as a lead radiotracer for our positron emission tomography (PET) program. Efficient carbon-11 radiolabeling afforded [11C]9 in high radiochemical yields (isolated RCY, 25.9% ± 5.7%). In vitro autoradiographic studies in rat brain and TrkB-expressing human neuroblastoma cryosections confirmed that [11C]9 specifically binds to Trk receptors in vitro. MicroPET studies revealed that binding of [11C]9 in the rodent brain was mostly nonspecific despite initial high brain uptake (SUVmax = 2.0). Modeling studies of the 4-aza-2-oxindole scaffold led to the successful identification of a small series of high affinity fluorinated and methoxy derivatized pan-Trk inhibitors based on our lead compound 9. Out of this series, the fluorinated compound 10 was selected for initial evaluation and radiolabeled with fluorine-18 (isolated RCY, 2.5% ± 0.6%). Compound [18F]10 demonstrated excellent Trk selectivity in a panel of cancer relevant kinase targets and a promising in vitro profile in tumors and brain sections but high oxidative metabolic susceptibility leading to nonspecific brain distribution in vivo. The information gained in this study will guide further exploration of the 4-aza-2-oxindole scaffold as a lead for Trk PET ligand development.
Read the peer-reviewed publication
radiochemical yieldsTrk PET Imaging AgentsTropomyosin receptor kinasesrat brainTrk radiopharmaceuticalspositron emission tomographycompound 9.neuroblastoma cryosectionsTrk PET ligand developmentTrk selectivitybrain uptakeMicroPET studiesRCYbrain distributionbrain sectionscompound 10Trk receptorsautoradiographic studiesrodent brainkinase targets